profit from every $100 of sales.
$0$100
Femasys
$1.42+1.43% today
+71.8% in 1 year
1-year low $0.721-year high $17.34
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Femasys sold, what it kept, and what it did with the cash.
Sales went from $1.21 million in 2022 to $2.29 million in 2025, with -$18.6 million of profit last year.
SalesProfit
Femasys vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Femasys | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Femasys's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 1 | 2 | 2 | |
| 1 | 1 | 1 | 1 | |
| -12 | -15 | -18 | -18 | |
| -10 | -13 | -16 | -16 | |
| -11 | -14 | -19 | -19 | |
| -19.20 | -18.60 | -17.00 | -9.40 | |
| 63.4% | 64.5% | 66.6% | 62.0% | |
| -961.7% | -1,353.4% | -1,091.8% | -767.0% | |
| -944.6% | -1,329.1% | -1,155.0% | -812.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17 | 28 | 12 | 21 |
| Cash | 13 | 22 | 3 | 9 |
| Total debt | 1 | 7 | 7 | 5 |
| Total liabilities | 2 | 9 | 10 | 15 |
| 15 | 18 | 2 | 6 | |
| 1 | 1 | 1 | 2 | |
| -56.9% | -44.4% | -139.4% | -125.1% | |
| -74.8% | -77.6% | -816.5% | -317.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -11 | -19 | -19 | |
| 0 | 0 | 1 | 1 | |
| -11 | -11 | -20 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 0 | 1 |
Valuation
- –
- –
- –
- 3.9×
- 5.2×
- –
- –
- -162.5%
- -156.6%
- 0.0%
Profitability
- 62.0%
- -767.0%
- -812.3%
- -416.9%
- 611.3%
- -105.2%
- -258.1%
- 0.0%
- 518.3%
- 249.0%
Growth
- +23.9%
- –
- +4.9%
- –
- +35.3%
Financial health
- -0.3×
- 0.65
- 0.0%
- -13.0×
- –
- –
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 22%of 911
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | 0.00 | -0.07 | +107.3% |
| Mar 31, 2026 | -0.01 | -0.08 | +88.0% |
| Nov 14, 2025 | -0.10 | -0.12 | +13.0% |
| Aug 8, 2025 | -0.16 | -0.18 | +11.1% |
| May 8, 2025 | -0.23 | -0.17 | −35.3% |
| Mar 27, 2025 | -0.23 | -0.25 | +8.0% |
| Nov 12, 2024 | -0.24 | -0.20 | −20.0% |
| Aug 8, 2024 | -0.21 | -0.18 | −16.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
19No pass
Philip Fisher
60Pass
Peter Lynch
91Pass
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
54No pass
Questions about Femasys
Is Femasys a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Femasys AI analysis
What does Femasys do?
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. It is in Medical - Instruments & Supplies.
Does Femasys pay a dividend?
No. Femasys does not pay a dividend at the moment.
Is Femasys stock halal?
No. Femasys does not pass our halal screen: its debt is 40% of its market value, at or above the 33% limit. How we check
How has Femasys stock done over the past year?
Up 71.8% over the past twelve months, to $1.42. It traded between $0.72 and $17.34 and is 91.8% below its high.
Who are Femasys's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Femasys's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.